Merck & Co., Inc. (MRK)
NYSE: MRK · Real-Time Price · USD
115.84
+2.47 (2.18%)
At close: Feb 3, 2026, 4:00 PM EST
115.53
-0.31 (-0.27%)
After-hours: Feb 3, 2026, 7:59 PM EST
Merck & Co. Employees
As of December 31, 2024, Merck & Co. had 75,000 total employees, including 73,000 full-time and 2,000 part-time employees. The number of employees increased by 3,000 or 4.17% compared to the previous year.
Employees
75,000
Change (1Y)
3,000
Growth (1Y)
4.17%
Revenue / Employee
$866,813
Profits / Employee
$243,387
Market Cap
287.52B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 75,000 | 3,000 | 4.17% |
| Dec 31, 2023 | 72,000 | 3,000 | 4.35% |
| Dec 31, 2022 | 69,000 | 1,000 | 1.47% |
| Dec 31, 2021 | 68,000 | -6,000 | -8.11% |
| Dec 31, 2020 | 74,000 | 3,000 | 4.23% |
| Dec 31, 2019 | 71,000 | 2,000 | 2.90% |
| Dec 31, 2018 | 69,000 | 0 | - |
| Dec 31, 2017 | 69,000 | 1,000 | 1.47% |
| Dec 31, 2016 | 68,000 | 0 | - |
| Dec 31, 2015 | 68,000 | -2,000 | -2.86% |
| Dec 31, 2014 | 70,000 | -6,000 | -7.89% |
| Dec 31, 2013 | 76,000 | -7,000 | -8.43% |
| Dec 31, 2012 | 83,000 | -3,000 | -3.49% |
| Dec 31, 2011 | 86,000 | -8,000 | -8.51% |
| Dec 31, 2010 | 94,000 | -6,000 | -6.00% |
| Dec 31, 2009 | 100,000 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
| Company Name | Employees |
|---|---|
| Johnson & Johnson | 138,100 |
| Sanofi | 82,878 |
| Pfizer | 81,000 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| GSK plc | 68,629 |
| AbbVie | 55,000 |
| Eli Lilly and Company | 47,000 |
MRK News
- 9 hours ago - Merck & Co., Inc. (MRK) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 12 hours ago - Merck's Annual Outlook Falls Short But Keytruda, Animal Health Segments Grow - Benzinga
- 16 hours ago - Merck tops Q4 earnings expectations but issues weaker 2026 outlook - Invezz
- 16 hours ago - Merck's outlook for 2026 comes in lower-than-expected as pipeline faces make-or-break year - Market Watch
- 16 hours ago - Merck Earnings Top Estimates. Why the Stock Is Falling. - Barrons
- 16 hours ago - Merck Expects Slower Earnings Growth As It Spends on Acquisitions - WSJ
- 16 hours ago - Merck forecasts 2026 sales below estimates on patent losses - Reuters
- 16 hours ago - Merck tops quarterly estimates, posts modest 2026 guidance as generic competition looms - CNBC